| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | ETM |
| Uniprot No | P11039 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-113aa |
| 氨基酸序列 | MDALHGICVNINKFYKCRRIVIEYDNCSASFTFNCVHDNRKVNCLEIVGLRRNEYVCLGKIINGDKIISVHENSVNGKIIVPVEDTFDFGLFTLKNKITDAVIKLNVYINETS |
| 预测分子量 | 12,8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ETM重组蛋白的参考文献示例(注：以下内容为虚构，仅作格式参考)：
1. **文献名称**：*Structural and Functional Analysis of Recombinant ETM Protein Complex in Viral Envelopes*
**作者**：Li, X. et al.
**摘要**：本研究通过哺乳动物表达系统成功表达并纯化了ETM(E-Transmembrane-M)重组蛋白复合体，利用冷冻电镜技术解析其三维结构，揭示了跨膜结构域在病毒包膜组装中的关键作用，为抗病毒药物开发提供理论依据。
2. **文献名称**：*Expression and Immunogenicity Evaluation of ETM-Based Recombinant Subunit Vaccine*
**作者**：Wang, Y. et al.
**摘要**：通过大肠杆菌表达系统高效制备ETM重组蛋白，并在小鼠模型中验证其作为亚单位疫苗的免疫原性，结果显示显著的中和抗体应答，表明其在预防冠状病毒感染中的潜在应用价值。
3. **文献名称**：*Optimization of ETM Recombinant Protein Production in Baculovirus-Insect Cell System*
**作者**：Smith, J. et al.
**摘要**：系统优化杆状病毒-昆虫细胞表达体系中ETM蛋白的产量和可溶性，结合亲和层析纯化技术获得高纯度蛋白，为大规模生产用于结构研究和诊断试剂开发奠定基础。
4. **文献名称**：*Role of ETM Recombinant Protein in Membrane Fusion and Viral Pathogenesis*
**作者**：Zhang, H. et al.
**摘要**：通过体外膜融合实验和分子动力学模拟，阐明ETM重组蛋白中跨膜结构域对病毒宿主细胞膜融合的调控机制，为靶向膜融合的抑制剂设计提供新思路。
**注**：以上文献为示例性内容，实际研究中请通过学术数据库检索真实文献。
ETM recombinant proteins are engineered fusion proteins designed to enhance antigenicity, stability, or functional versatility in biomedical applications. The term "ETM" typically refers to Epitope-Tagged Multi-epitope, a design strategy that combines multiple immunogenic epitopes or functional domains into a single polypeptide chain. This approach leverages recombinant DNA technology to fuse sequences encoding selected epitopes (e.g., viral antigens, tumor-associated markers) with linker peptides and purification tags (e.g., His-tag, FLAG-tag), enabling efficient production in heterologous expression systems like *E. coli*, yeast, or mammalian cells.
Developed to address challenges in vaccine design and diagnostic tool development, ETM proteins aim to overcome limitations of single-epitope vaccines, such as narrow immune coverage and rapid pathogen escape. By integrating conserved or immunodominant epitopes from multiple strains or pathogens, they can elicit broader cross-reactive immune responses. For instance, ETM-based candidates have been explored against rapidly mutating viruses (e.g., influenza, HIV) and complex diseases like cancer.
The modular architecture of ETM proteins allows customizable configurations tailored to specific targets. Advanced computational tools aid epitope selection based on HLA binding affinity, population coverage, and structural stability. Post-translational modifications (e.g., glycosylation) in eukaryotic systems further enhance their physiological relevance. Purification is streamlined via affinity tags, ensuring high yield and purity for immunological assays or therapeutic formulations.
Current research focuses on optimizing delivery systems (nanoparticles, viral vectors) and adjuvant compatibility to improve immunogenicity. ETM platforms are also adapted for diagnostics, serving as capture antigens in serological assays. Their versatility positions ETM recombinant proteins as promising tools for next-generation precision medicine and global health challenges.
×
